Logo Magicbullet
Hintergrundbild
 
Universität Bielefeld > Fakultät für Chemie > Organische Chemie III > Magicbullet > PhD Students
  

General Information

Ivan Randelovic Ivan Randelovic
21/01/1986
Serbian


Scientific Education

since 09/2015

Marie Skłodowska-Curie PhD fellow at National Institute of Oncology, Budapest, Hungary - Department of Experimental Pharmacology, supervised by Dr. József Tóvári. Early Stage Researcher in Marie Skodowska-Curie Innovative Training Network (ITN-ETN) "Peptide-Drug Conjugates for Targeted Delivery in Tumor Therapy" (MAGICBULLET); Grant no: 642004. PhD topic: Investigation of the effect of peptide-drug bio-conjugates on tumor growth and metastasis in vitro and in vivo
PhD student on Semmelweis University - Doctoral School of Pathological Sciences, program: Experimental Oncology, Budapest, Hungary

since 11/2014

M.Sc. in Molecular Biology and Physiology
University of Belgrade, Belgrade, Serbia
Faculty of Biology
Department for Molecular Biology and Physiology
Experimental Biomedicine
Master thesis: "Anticancer activity of neutral and cationic Iridium (III) complexes with Ph2PCH2S(O)xPh (x=0-2) ligands." - Department of Immunology - Cancer Group, Institute for Biological Research "Siniša Stanković" (IBISS), University of Belgrade, Serbia – supervised by Prof. Dr. Danijela Maksimović-Ivanić, Prof. Dr. Sanja Mijatović and Prof. Dr. Bato Korać
Full tuition fee scholarship given by Ministry of Education, Science and Technological Development of the Republic of Serbia, and University of Belgrade during all years of study

Work experience

09/2012 – 11/2014

Researcher at the Department of Immunology - Cancer Group, Institute for Biological Research "Siniša Stanković" (IBISS) in Belgrade, Serbia (Head of the Department: Prof. Dr. Stanislava Stošić-Grujićić, MD, PhD)
The project: "Molecular mechanisms of physiological and pharmacological control of inflammation and cancer" (No. 173013) funded by the Ministry of Education, Science and Technological Development of the Republic of Serbia Research topic: Testing and evaluation of new therapeutics (natural or synthetic origin) with anticancer properties in the treatment of cancer cell lines in vitro, and animal tumor models in vivo, and determine their molecular mechanisms of action and signaling pathways that modulate the response to cancer therapies
Collaboration with Prof. Dr. Dirk Steinborn group, Institute of Chemistry, Martin Luther University Halle-Wittenberg, Halle, Germany

Publications

  • A. Gronewold, M. Horn, I. Ranđelović, J. Tóvári, S. Muñoz Vázquez, K. Schomäcker, I. Neundorf, Back cover: "Characterization of a Cell-Penetrating Peptide with Potential Anticancer Activity", ChemMedChem, 2017, 12(1): 104-104. doi: 10.1002/cmdc.201600624
  • A. Gronewold, M. Horn, I. Ranđelović, J. Tóvári, S. Muñoz Vázquez, K. Schomäcker, I. Neundorf, "Characterization of a Cell-Penetrating Peptide with Potential Anticancer Activity", ChemMedChem, 2017, 12(1): 42-49. doi: 10.1002/cmdc.201600498
  • G. Ludwig, I. Ranđelović, D. Maksimović-Ivanić, S. Mijatović, M. Bulatović, Dj. Miljković, M. Korb, H. Lang, D. Steinborn, G. Kaluđerović, "Anticancer Potential of (Pentamethylcyclopentadienyl)chlorido iridium(III) Complexes Bearing kP and kP,kS-Coordinated Ph2PCH2CH2CH2S(O)xPh (x=0-2) Ligands", Chem Med Chem, 2014, 9: 1586-93. doi: 10.1002/cmdc.201300479
  • G. Ludwig, S. Mijatović, I. Ranđelović, M. Bulatović, Dj. Miljković, D. Maksimović-Ivanić, M. Korb, H. Lang, D. Steinborn, G. Kaluđerović, "Biological Activity of Neutral and Cationic Iridium(III) Complexes with kP and kP, kS coordinated Ph2PCH2S(O)xPh (x = 0–2) Ligands", European Journal of Medicinal Chemistry, 2013, 69: 216-22. doi: 10.1016/j.ejmech.2013.08.025

Presentations

  • Poster presentation: A.A.P. Tripodi, I. Randelovic, K.N Enyedi, J. Tóvári, G. Mezõ, "Development of novel cyclic RGD and NGR peptide drug-conjugates for tumor targeting", at the 34th European Peptide Symposium in Leipzig, Germany, September 4th to 9th, 2016